The Satellite Symposium of the ISA 2015 in Tokyo

Program
Opening Remarks (Video Letter)

Lecture Room 1  May 21st (Thu.) 9:20 a.m. - 9:30 a.m.

Philip Barter
President of the International Atherosclerosis Society/The University of New South Wales

Sponsored Symposium 1

Lecture Room 1  May 21st (Thu.) 9:30 a.m. - 11:00 a.m.

SS1  Epidemiology and Current Care of FH in the Asia Pacific Region

Chairs: Junji Kobayashi
Department of General Medicine, Kanazawa Medical University
Tomonori Okamura
Department of Preventive Medicine and Public Health, School of Medicine, Keio University

SS1-1  Epidemiology and Care of FH in Australia
David Sullivan¹, Gerald F Watts²
¹Department of Chemical Pathology, Royal Prince Alfred Hospital, ²Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, University of Western Australia.

SS1-2  Update of Familial Hypercholesterolemia Management in Japan
Hidenori Arai
National Center for Geriatrics and Gerontology

SS1-3  Epidemiology of FH in China
Dong Zhao
Beijing Institute of Heart, Lung & Blood Vessel Diseases, the Department of Epidemiology of BIHLBD, Capital Medical University Beijing Anzhen Hospital

SS1-4  Epidemiology and Current Care of Homozygous FH
Atsushi Nohara
Lipidology Research Unit, Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Sciences

Amgen Astellas BioPharma K.K.
Sponsored Symposium 2

**Lecture Room 1** May 21st (Thu.) 11:00 a.m. - 12:30 p.m.

**SS2** Management of Vascular Complications in FH

Chairs: Jeong Euy Park
Sungkyunkwan University Medical School
Masayuki Yokode
Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto University Graduate School of Medicine

**SS2-1** Management of Vascular Complications of FH in Korea
Sang-Hak Lee
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine

**SS2-2** Management of Familial Hypercholesterolemia in Hong Kong
Teresa Miao Hu, Brian Tomlinson
Department of Medicine & Therapeutics, The Chinese University of Hong Kong

**SS2-3** Vascular Complications of Japanese FH Patients
Masa-aki Kawashiri
Department of Internal Medicine, Institution of Medical, Pharmaceutical and Health Sciences, Kanazawa University

**SS2-4** Cholesterol Efflux Capacity as a Residual Risk Factor in FH Patients
Masatsune Ogura
National Cerebral and Cardiovascular Center

Kowa Company, Ltd./ SHIONOGI & CO., LTD.

Luncheon Seminar 1

**Lecture Room 1** May 21st (Thu.) 12:40 p.m. - 1:30 p.m.

**LS1** Residual Risk Management in Patients with Cardiometabolic Risk

Chairs: Piyamitr Sritara
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Soo Lim
Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital

**LS1-1** Postprandial Dyslipidemia; Previously Unrecognized Link between High Fat Diet and Vascular Inflammation
Masayuki Yoshida
Department of Life Science and Bioethics, Graduate School of Medicine, Tokyo Medical and Dental University

**LS1-2** Holistic Management of Diabetes: New Promises for the High Risk Group
Shun Ishibashi
Department of Internal Medicine, Division of Endocrinology and Metabolism, Jichi Medical University

Kowa Company, Ltd./ Kowa Pharmaceutical Company, Ltd.
Plenary Lecture

**Lecture Room 1**
May 21st (Thu.) 1:40 p.m.-2:20 p.m.

**PL**

**Chair:** Yuji Matsuzawa  
Sumitomo Hospital

**International Developments for Improving the Care of FH**

Gerald F Watts  
Lipid Disorders Clinic, Cardiovascular Medicine Centre, Royal Perth Hospital, University of Western Australia; FH Australasia Network and International FH Foundation.

---

Luncheon Seminar 2

**Lecture Room 2**
May 21st (Thu.) 12:40 p.m. - 1:30 p.m.

**LS2**

**Familial Hypercholesterolemia and Reverse Cholesterol Transport System**

**Chairs:** Yasuyoshi Ouchi  
Toranomon Hospital  
Hsu Tsui-Lieh  
Taipei Veterans General Hospital

**LS2-1**

**Clinical Features and Treatment of Familial Hypercholesterolemia**

Takashi Miida  
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine

**LS2-2**

**Anti-atherosclerotic Potential of Probucol, a Cholesterol-lowering Antioxidant, in Long-term Treatment for Patients with Familial Hypercholesterolemia**

Hideaki Bujo  
Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center

Otsuka Pharmaceutical Co., Ltd.
### Symposium

**Lecture Room 1**

**May 21st (Thu.) 4:20 p.m. - 6:20 p.m.**

<table>
<thead>
<tr>
<th>SS3</th>
<th>Current Drug Therapy for FH</th>
</tr>
</thead>
<tbody>
<tr>
<td>SS3-1</td>
<td>Cholesterol Absorption Inhibition in the Management of Familial Hypercholesterolemia</td>
</tr>
<tr>
<td>SS3-2</td>
<td>Evidences of Probucol in Japanese Patients with Familial Hypercholesterolemia</td>
</tr>
<tr>
<td>SS3-3</td>
<td>Statin in Prevention of Cardiovascular Disease</td>
</tr>
<tr>
<td>SS3-4</td>
<td>Management of Familial Hypercholesterolemia: Lifestyle Modification</td>
</tr>
</tbody>
</table>

### S

**Outlook for New Treatment for FH**

**Lecture Room 1**

**May 21st (Thu.) 4:20 p.m. - 6:20 p.m.**

| S-1 | New Treatments for Familial Hypercholesterolaemia-PCSK 9 Inhibition |
| S-2 | Living Donor Liver Transplantation for Homozygous Familial Hypercholesterolemia |
| S-3 | Cell Transplantation Therapy for Homozygous Familial Hypercholesterolemia Patients—Current Status of Phase I Trial of Transplantation Therapy with Allogeneic Adipose Tissue-derived Multilineage Progenitor Cells— |
| S-4 | Roles of Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, in the Treatment of Familial Hypercholesterolemia |
| S-5 | Development of Antisense Drug for Dyslipidemia |
Closing Remarks (Video Letter)

Lecture Room 1  May 21st (Thu.) 6:20 p.m. - 6:30 p.m.
John JP Kastelein
The Academic Medical Center of The University of Amsterdam